Literature DB >> 21959973

Human tissue kallikrein 1 gene delivery inhibits PDGF-BB-induced vascular smooth muscle cells proliferation and upregulates the expressions of p27Kip1 and p2lCip1.

Hui-Zhen Yu1, Liang-di Xie, Peng-li Zhu, Chang-sheng Xu, Hua-jun Wang.   

Abstract

Tissue kallikrein 1 cleaves kininogen substrate to produce vasoactive kinin peptides that have been implicated in inhibiting neointimal hyperplasia in rat carotid arteries after balloon injury. However, its effects on the proliferation, cell cycle and its mechanisms, for example, cyclin-dependent kinase inhibitors, p27(Kip1) and p2l(Cip1) in vascular biology are poorly understood. The objective of this study was to explore the effects of human tissue kallikrein 1 (hTK1) mediated by recombinant adenovirus (Ad-hTK1) on proliferation and cell cycle of vascular smooth muscle cells (VSMCs) derived from spontaneously hypertensive rats induced by platelet-derived growth factor-BB (PDGF-BB) in vitro. The results showed that, within a given multiplicity of infection (MOI) and time, the hTK1 gene delivery inhibited PDGF-BB-stimulating VSMCs growth in a concentration-dependent (20-100 MOI) and time-dependent (2-5 days) manner by cell counting, with a peak inhibition rate at 36.3% at 72 h (P < 0.01). In addition, hTK1 gene delivery significantly suppressed PDGF-BB-induced proliferation of VSMCs by methyl thiazolyl tetrazoliuin assay, and decreased the percentage of cells in the S phase and in DNA synthesis by flow cytometry, with a peak inhibition rate at 30.2 and 36.4%, respectively (P < 0.01). Western blot assay showed that the protein levels of p27(Kip1) and p2l(Cip1) in cells infected with Ad-hTK1 were much more abundant than those in cells only induced by PDGF-BB, with up-modulating rates at 51.8 and 58.7%, respectively (P < 0.001). We also observed that the effects of hTK1 gene delivery in inhibiting VSMCs proliferation, arresting cell cycling in G(0)/G(1) phase and up-regulating the expression of p27(Kip1) and p2l(Cip1) could be blocked by icatibant (Hoe 140), a specific bradykinin B(2) receptor antagonist. Taken together, these results demonstrated that hTK1 overexpressed by recombinant adenovirus potently inhibits VSMCs proliferation that is required for neointimal hyperplasia and restenosis, and may activate p27(Kip1) and p2l(Cip1) signaling pathways via bradykinin B(2) receptor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959973     DOI: 10.1007/s11010-011-1076-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  32 in total

1.  Development of a strain of spontaneously hypertensive rats.

Authors:  K OKAMOTO; K AOKI
Journal:  Jpn Circ J       Date:  1963-03

2.  Mutated p21/WAF/CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidation-sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice.

Authors:  G Condorelli; J K Aycock; G Frati; C Napoli
Journal:  FASEB J       Date:  2001-10       Impact factor: 5.191

3.  Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty.

Authors:  H Murakami; K Yayama; R Q Miao; C Wang; L Chao; J Chao
Journal:  Hypertension       Date:  1999-08       Impact factor: 10.190

4.  Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats.

Authors:  J Chao; K X Chai; L M Chen; W Xiong; S Chao; C Woodley-Miller; L X Wang; H S Lu; L Chao
Journal:  J Biol Chem       Date:  1990-09-25       Impact factor: 5.157

5.  Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis.

Authors:  Chun-Fang Xia; Hang Yin; Yu-Yu Yao; Cesar V Borlongan; Lee Chao; Julie Chao
Journal:  Hum Gene Ther       Date:  2006-02       Impact factor: 5.695

6.  Effects of kinins on cultured arterial smooth muscle.

Authors:  B S Dixon; R Breckon; J Fortune; R J Vavrek; J M Stewart; R Marzec-Calvert; S L Linas
Journal:  Am J Physiol       Date:  1990-02

Review 7.  Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy.

Authors:  Subbareddy Maddika; Sudharsana Rao Ande; Soumya Panigrahi; Ted Paranjothy; Kazimierz Weglarczyk; Anne Zuse; Mehdi Eshraghi; Kamala D Manda; Emilia Wiechec; Marek Los
Journal:  Drug Resist Updat       Date:  2007-02-14       Impact factor: 18.500

8.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

9.  Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells.

Authors:  L M Graves; K E Bornfeldt; E W Raines; B C Potts; S G Macdonald; R Ross; E G Krebs
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

10.  Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle.

Authors:  C Emanueli; A Zacheo; A Minasi; J Chao; L Chao; M B Salis; T Stacca; S Straino; M C Capogrossi; P Madeddu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-11       Impact factor: 8.311

View more
  8 in total

1.  Silencing heat shock protein 27 (HSP27) inhibits the proliferation and migration of vascular smooth muscle cells in vitro.

Authors:  Jie Huang; Liang-di Xie; Li Luo; Su-Li Zheng; Hua-Jun Wang; Chang-Sheng Xu
Journal:  Mol Cell Biochem       Date:  2014-01-28       Impact factor: 3.396

2.  Fluvastatin upregulates the α 1C subunit of CaV1.2 channel expression in vascular smooth muscle cells via RhoA and ERK/p38 MAPK pathways.

Authors:  Qiu-Fang Ouyang; Ying Han; Zhi-Hong Lin; Hong Xie; Chang-Sheng Xu; Liang-Di Xie
Journal:  Dis Markers       Date:  2014-12-30       Impact factor: 3.434

3.  Danhong injection reduces vascular remodeling and up-regulates the Kallikrein-kinin system in spontaneously hypertensive rats.

Authors:  Xiaohu Yang; John Orgah; Dandan Wang; Guanwei Fan; Hu Jingyang; Jihong Han; Gangjian Qin; Xiumei Gao; Yan Zhu
Journal:  Sci Rep       Date:  2017-06-27       Impact factor: 4.379

4.  High Level of Serum Tissue Kallikrein Is Associated with Favorable Outcome in Acute Ischemic Stroke Patients.

Authors:  Fei Wu; Yifeng Ling; Lumeng Yang; Xin Cheng; Qiang Dong; Wenjie Cao
Journal:  Dis Markers       Date:  2019-06-02       Impact factor: 3.434

5.  Co‑expression of tissue kallikrein 1 and tissue inhibitor of matrix metalloproteinase 1 improves myocardial ischemia‑reperfusion injury by promoting angiogenesis and inhibiting oxidative stress.

Authors:  Shujie Huang; Meixian Chen; Huizhen Yu; Kaiyang Lin; Yansong Guo; Pengli Zhu
Journal:  Mol Med Rep       Date:  2020-12-23       Impact factor: 2.952

6.  Tissue Kallikrein Activity, Detected by a Novel Method, May Be a Predictor of Recurrent Stroke: A Case-Control Study.

Authors:  Xiao Ran; Qin Zhang; Dao Wen Wang
Journal:  Dis Markers       Date:  2015-09-14       Impact factor: 3.434

7.  Synergistic effect of a tissue kallikrein 1 and tissue inhibitor of matrix metalloproteinase 1 co‑expression vector on the proliferation of rat vascular smooth muscle cells.

Authors:  Pengli Zhu; Huizhen Yu; Shujie Huang; Hong Xiang; Feng Li; Weiping Zheng
Journal:  Mol Med Rep       Date:  2015-08-07       Impact factor: 2.952

8.  Tissue Kallikrein Prevents Restenosis After Stenting of Severe Atherosclerotic Stenosis of the Middle Cerebral Artery: A Randomized Controlled Trial.

Authors:  Ruifeng Shi; Renliang Zhang; Fang Yang; Min Lin; Min Li; Ling Liu; Qin Yin; Hang Lin; Yunyun Xiong; Wenhua Liu; Xiaobing Fan; Qiliang Dai; Lizhi Zhou; Wenya Lan; Qinqin Cao; Xin Chen; Gelin Xu; Xinfeng Liu
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.